AbbVie Completes Acquisition of Nimble Therapeutics

Acquisition Overview - AbbVie has completed the acquisition of Nimble Therapeutics, integrating it into its operations [1] - The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor for psoriasis, currently in preclinical development [2] - Nimble's proprietary peptide synthesis, screening, and optimization platform is now part of AbbVie's R&D capabilities [2] Strategic Benefits - The acquisition strengthens AbbVie's immunology pipeline by adding novel oral peptide assets [3] - AbbVie aims to integrate Nimble's proprietary technology to enhance its R&D capabilities [3] - The talented team from Nimble, known for their commitment to improving care for autoimmune diseases, has joined AbbVie [3] Company Background - AbbVie focuses on discovering and delivering innovative medicines across key therapeutic areas including immunology, oncology, neuroscience, and eye care [4] - The company also offers products and services under its Allergan Aesthetics portfolio [4]